Clinical trial · Interventional
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
NCT00610883CI-TRIAL-00070015completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: * Induction ends on day 19 * Consolidation ends on day 38 or 42 * Maintenance may include up to 6 cycles
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1 - LSA4
- interventionNames
- Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
Primary outcomes (1)
- measure
- Complete Remission
- timeFrame
- 330 Days
- description
- The number of patients who achieved a complete remission as a result of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Non-Hodgkin's Lymphoma stages III, IV, IVA with 1. T cell lymphomas, any primary site irrespective of LDH level 2. large cell lymphomas, any primary site irrespective of LDH level 3. B cell lymphomas, any primary site with initial LDH of less than 500 Exclusion Criteria: * B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement
References
Publications (0)
Data not yet available
No reference posted for this study.